Teva Pharmaceutical Industries Limited (NYSE:TEVA)‘s stock had its “hold” rating reaffirmed by research analysts at Maxim Group in a research report issued on Thursday. They currently have a $35.00 target price on the stock. Maxim Group’s price target would indicate a potential upside of 9.96% from the stock’s previous close.

TEVA has been the subject of a number of other research reports. Oppenheimer Holdings, Inc. set a $43.00 price objective on Teva Pharmaceutical Industries Limited and gave the company a “buy” rating in a research report on Thursday, April 6th. Cantor Fitzgerald set a $31.00 price objective on Teva Pharmaceutical Industries Limited and gave the company a “hold” rating in a research report on Thursday, June 22nd. Credit Suisse Group reiterated a “buy” rating and set a $39.00 price target on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday, May 17th. BidaskClub upgraded Teva Pharmaceutical Industries Limited from a “strong sell” rating to a “sell” rating in a research report on Tuesday, June 13th. Finally, Vetr upgraded Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating and set a $33.12 price target for the company in a research report on Tuesday, May 2nd. Sixteen research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $42.78.

Shares of Teva Pharmaceutical Industries Limited (TEVA) opened at 31.80 on Thursday. The firm’s 50-day moving average is $30.42 and its 200 day moving average is $32.94. The firm has a market cap of $32.31 billion, a PE ratio of 407.69 and a beta of 0.46. Teva Pharmaceutical Industries Limited has a 52 week low of $27.59 and a 52 week high of $55.79.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last released its quarterly earnings data on Thursday, May 11th. The company reported $1.06 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $1.06. Teva Pharmaceutical Industries Limited had a return on equity of 16.38% and a net margin of 1.49%. The business had revenue of $5.63 billion during the quarter, compared to analyst estimates of $5.69 billion. During the same quarter in the previous year, the firm posted $1.20 EPS. The business’s revenue for the quarter was up 17.0% compared to the same quarter last year. Equities research analysts forecast that Teva Pharmaceutical Industries Limited will post $4.76 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This story was first reported by Watch List News and is the property of of Watch List News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. & international trademark and copyright laws. The original version of this story can be viewed at https://www.watchlistnews.com/maxim-group-reiterates-hold-rating-for-teva-pharmaceutical-industries-limited-teva/1445222.html.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Alliancebernstein L.P. raised its position in Teva Pharmaceutical Industries Limited by 7.3% in the first quarter. Alliancebernstein L.P. now owns 8,617,143 shares of the company’s stock valued at $276,524,000 after buying an additional 587,286 shares during the last quarter. Camber Capital Management LLC raised its position in Teva Pharmaceutical Industries Limited by 10.4% in the first quarter. Camber Capital Management LLC now owns 5,216,450 shares of the company’s stock valued at $167,396,000 after buying an additional 492,000 shares during the last quarter. Renaissance Technologies LLC raised its position in Teva Pharmaceutical Industries Limited by 122.4% in the first quarter. Renaissance Technologies LLC now owns 4,817,763 shares of the company’s stock valued at $154,602,000 after buying an additional 2,651,900 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. raised its position in Teva Pharmaceutical Industries Limited by 21.3% in the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 4,564,560 shares of the company’s stock valued at $165,461,000 after buying an additional 801,106 shares during the last quarter. Finally, State Street Corp raised its position in Teva Pharmaceutical Industries Limited by 15.9% in the first quarter. State Street Corp now owns 4,530,768 shares of the company’s stock valued at $145,390,000 after buying an additional 621,795 shares during the last quarter. 56.26% of the stock is currently owned by hedge funds and other institutional investors.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.